169例上皮性卵巢癌患者血清CA125的临床相关因素
The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma.
作者信息
Hawkins R E, Roberts K, Wiltshaw E, Mundy J, McCready V R
机构信息
Department of Medicine, Royal Marsden Hospital, London, UK.
出版信息
Br J Cancer. 1989 Oct;60(4):634-7. doi: 10.1038/bjc.1989.329.
Abstract
Serial CA125 measurements in 169 patients with epithelial ovarian carcinoma were obtained. Changes in serum CA125 measurements are shown to reflect changes in clinical status. For patients with macroscopic disease receiving chemotherapy, the sensitivity and specificity for predicting response are shown to be 95% and 86% respectively. For patients with no known disease, the sensitivity and specificity for detecting relapse are shown to be 86% and 91% respectively. The clinical correlates with the level of serum CA125 were examined and the most important is shown to be amount of residual disease.
摘要
对169例上皮性卵巢癌患者进行了连续的CA125检测。血清CA125检测结果的变化被证明可反映临床状态的变化。对于接受化疗的有肉眼可见病灶的患者，预测反应的敏感性和特异性分别为95%和86%。对于无已知病灶的患者，检测复发的敏感性和特异性分别为86%和91%。研究了血清CA125水平与临床指标的相关性，结果显示最重要的指标是残留病灶量。
相似文献
1
The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma.169例上皮性卵巢癌患者血清CA125的临床相关因素
Br J Cancer. 1989 Oct;60(4):634-7. doi: 10.1038/bjc.1989.329.
2
CA125-response assessment in epithelial ovarian cancer.上皮性卵巢癌中CA125反应评估
Int J Cancer. 1992 Apr 22;51(1):58-61. doi: 10.1002/ijc.2910510112.
3
[Primary research on saliva and serum CA125 assays for detecting malignant ovarian tumors].唾液和血清CA125检测用于卵巢恶性肿瘤诊断的初步研究
Zhonghua Fu Chan Ke Za Zhi. 1990 Mar;25(2):84-5, 123-4.
4
Immunoassay of CA125 in ovarian cancer: a comparison of three assays for use in diagnosis and monitoring.卵巢癌中CA125的免疫测定：三种用于诊断和监测的测定方法的比较
Dis Markers. 1989 Jan-Mar;7(1):61-7.
5
A CA125 score as a prognostic index in patients with ovarian cancer.
Arch Gynecol Obstet. 1990;247(3):125-9. doi: 10.1007/BF02390860.
6
CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer.
J Comput Assist Tomogr. 1993 Jul-Aug;17(4):626-32. doi: 10.1097/00004728-199307000-00021.
7
CA125 measurement in epithelial ovarian cancer: a 10-year anniversary of clinical investigation.上皮性卵巢癌中CA125检测：临床研究十周年
Gynecol Oncol. 1993 Apr;49(1):1-2. doi: 10.1006/gyno.1993.1075.
8
[CA125 and radioimmunoimaging in monitoring of epithelial ovarian carcinoma].[CA125与放射免疫显像在监测上皮性卵巢癌中的应用]
Zhonghua Fu Chan Ke Za Zhi. 1991 Jul;26(4):235-8, 252.
9
Evaluation of two new assays for tumor-associated antigens, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma--comparison with CA125.评估上皮性卵巢癌患者血清中发现的两种肿瘤相关抗原新检测方法CASA和OSA，并与CA125进行比较。
Gynecol Oncol. 1990 May;37(2):165-71. doi: 10.1016/0090-8258(90)90328-i.
10
[Clinical value of a new serum tumor marker CA602 in ovarian cancers].新型血清肿瘤标志物CA602在卵巢癌中的临床价值
Nihon Gan Chiryo Gakkai Shi. 1990 Jul 20;25(7):1454-60.
引用本文的文献
1
Percutaneous Radiofrequency Ablation Combined With Chemotherapy Versus Chemotherapy Only for Ovarian Cancer Liver Metastasis.经皮射频消融联合化疗与单纯化疗治疗卵巢癌肝转移的对比研究
Front Oncol. 2022 Jan 3;11:793024. doi: 10.3389/fonc.2021.793024. eCollection 2021.
2
Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction.通过CXCR2转导改善肿瘤腹水淋巴细胞向卵巢癌微环境的迁移。
Oncoimmunology. 2017 Dec 26;7(4):e1412029. doi: 10.1080/2162402X.2017.1412029. eCollection 2018.
3
Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement.肿瘤抗原CA125通过直接抗体结合和抑制Fc-γ受体结合来抑制抗体依赖性细胞毒性（ADCC）。
Oncotarget. 2017 Jul 7;8(32):52045-52060. doi: 10.18632/oncotarget.19090. eCollection 2017 Aug 8.
4
Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders.在患有良性妇科疾病的女性中，血清 HE4 水平升高的频率低于 CA125。
Am J Obstet Gynecol. 2012 Apr;206(4):351.e1-8. doi: 10.1016/j.ajog.2011.12.029. Epub 2011 Dec 30.
5
Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations.数学模型确定基于血液生物标志物的早期癌症检测策略和局限性。
Sci Transl Med. 2011 Nov 16;3(109):109ra116. doi: 10.1126/scitranslmed.3003110.
6
Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer.血清 HE4 与子宫内膜癌肿瘤大小和肌层浸润的相关性。
Gynecol Oncol. 2012 Feb;124(2):270-5. doi: 10.1016/j.ygyno.2011.10.025. Epub 2011 Oct 28.
7
Ovarian cancer: the duplicity of CA125 measurement.卵巢癌：CA125 检测的双重性。
Nat Rev Clin Oncol. 2010 Jun;7(6):335-9. doi: 10.1038/nrclinonc.2010.44. Epub 2010 Apr 6.
8
Current state of biomarker development for clinical application in epithelial ovarian cancer.上皮性卵巢癌临床应用中生物标志物的研究现状。
Gynecol Oncol. 2010 Feb;116(2):240-5. doi: 10.1016/j.ygyno.2009.09.041. Epub 2009 Oct 31.
9
Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer.82例上皮性卵巢癌患者中，集落刺激因子1的循环水平作为预后指标。
Br J Cancer. 1994 Feb;69(2):342-6. doi: 10.1038/bjc.1994.62.
本文引用的文献
1
Reactivity of a monoclonal antibody with human ovarian carcinoma.一种单克隆抗体与人卵巢癌的反应性。
J Clin Invest. 1981 Nov;68(5):1331-7. doi: 10.1172/jci110380.
2
Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types.一种识别浆液性、子宫内膜样和透明细胞型人卵巢肿瘤共同表面抗原的单克隆抗体的免疫病理学特征
Am J Clin Pathol. 1983 Jan;79(1):98-104. doi: 10.1093/ajcp/79.1.98.
3
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.一种使用单克隆抗体监测上皮性卵巢癌病程的放射免疫分析。
N Engl J Med. 1983 Oct 13;309(15):883-7. doi: 10.1056/NEJM198310133091503.
4
Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker.卵巢癌抗原CA125：对其作为肿瘤标志物作用的前瞻性临床评估
Br J Cancer. 1984 Dec;50(6):765-9. doi: 10.1038/bjc.1984.254.
5
6
Tumour-associated antigen CA 125 in patients with ovarian cancer.
Br J Obstet Gynaecol. 1985 May;92(5):528-31. doi: 10.1111/j.1471-0528.1985.tb01360.x.
7
Evaluation of serum CA125 values in healthy individuals and pregnant women.健康个体和孕妇血清CA125值的评估。
Am J Med Sci. 1986 Jul;292(1):25-9. doi: 10.1097/00000441-198607000-00005.
8
Explanation of the limited correlation between tumor CA 125 content and serum CA 125 antigen levels in patients with ovarian tumors.
Cancer. 1987 Nov 15;60(10):2437-42. doi: 10.1002/1097-0142(19871115)60:10<2437::aid-cncr2820601015>3.0.co;2-k.
9
Clinical significance of serum CA125 values in patients with cancers of the digestive system.
Am J Med Sci. 1986 Jul;292(1):30-4. doi: 10.1097/00000441-198607000-00006.
10
Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy.盆腔炎和妊娠时的卵巢癌抗原CA 125水平
Cancer. 1986 Apr 1;57(7):1327-9. doi: 10.1002/1097-0142(19860401)57:7<1327::aid-cncr2820570713>3.0.co;2-z.
Zotero 插件